Serelaxin a novel treatment for acute heart failure

Castrini, Anna Isotta; Carubelli, Valentina; Lazzarini, Valentina; Bonadei, Ivano; Lombardi, Carlo; Metra, Marco

doi:10.1586/17512433.2015.1073587

Cited by 8 publications

(7 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Serelaxin reduces systemic vascular resistance and increases blood flow to the renal vessels, increasing cardiac output. Serelaxin is also known to participate in various cellular processes with antioxidative, anti-inflammatory, and antifibrotic actions 41). A recent large-scale clinical trial found that the intravenous injection of serelaxin for 48 hours at the initial stage of AHF caused rapid hemodynamic improvement, which ameliorated symptoms associated with pulmonary congestion and improved some clinical outcomes including 180-day mortality 42)43)44)45).…”

Section: Pharmacological Treatmentmentioning

confidence: 99%

KSHF Guidelines for the Management of Acute Heart Failure: Part II. Treatment of Acute Heart Failure

et al. 2019

View full text Add to dashboard Cite

The prevalence of heart failure (HF) is on the rise due to the aging of society. Furthermore, the continuous progress and widespread adoption of screening and diagnostic strategies have led to an increase in the detection rate of HF, effectively increasing the number of patients requiring monitoring and treatment. Because HF is associated with substantial rates of mortality and morbidity, as well as high socioeconomic burden, there is an increasing need for developing specific guidelines for HF management. The Korean guidelines for the diagnosis and management of chronic HF were introduced in March 2016. However, chronic and acute HF represent distinct disease entities. Here, we introduce the Korean guidelines for the management of acute HF with reduced or preserved ejection fraction. Part II of this guideline covers the treatment of acute HF.

show abstract

Section: Pharmacological Treatmentmentioning

confidence: 99%

KSHF Guidelines for the Management of Acute Heart Failure: Part II. Treatment of Acute Heart Failure

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Serelaxin is a recombinant form of human relaxin-2 with vasodilator properties; this new molecule has two G-protein coupled receptors (RXFP1 and RXFP2), activation of these receptors can result in triggering NO synthase, that appears to be central in the vascular modulation effects of serelaxin [100][101][102]. The RELAX-AHF trial randomized 1161 patients, admitted for acute heart failure, to receive standard care plus 48 hours intravenous infusion of placebo or serelaxin (30 µg/Kg per day) [103].…”

Section: Vasodilatorsmentioning

confidence: 99%

Emerging and Traditional Treatment in Acute Heart Failure: Bad News from Last Interventional Trials

Alessandri¹,

Nuti²,

Palazzuoli³

2019

J Community Med Public Health

View full text Add to dashboard Cite

Over last two decades many drugs and Trials have been tested in order to improve Acute Heart failure (AHF) management and outcome. Despite recent findings showing significant improvements in the pharmacological management of chronic heart failure, in AHF patients no consistent benefits in terms of mortality and re-hospitalization rates have been found. Indeed, heart failure remains one of the leading causes of hospital admission in industrialized countries and relative costs is unacceptably high. Thus a therapeutic optimization and drug titration during hospitalization period to prevent future adverse event is one of the primary goals of treatment. Unfortunately, old and new drugs more recently attempted demonstrated contrasting results. In most of cases additional pharmacological treatment showed a transient improvement of some hemodynamic parameters such as wedge pressure reduction stroke volume improvement and congestion relief. Despite these apparently recover the mid and long term outcome revealed an insufficient trend. This is particularly true in patients in more severe hemodynamic picture, more advanced Heart failure and increased congestion burden. Inconsistent results could be due in part to the attempted drug inefficiency and partially to the study design and protocol that tested the same drug in several HF subtypes. In the light of this negative findings, we support the crucial relevance of emphasizing the heterogeneity through AHF clinical profiles, with different medical needs. Accordingly, in this review we report the main finding of the most important trials performed in AHF and we purpose a reappraisal of some attempted drugs looking for the primary HF deterioration mechanism, and the related prevalent pathophysiological disorder.

show abstract

“…Chronic heart failure progression is modifiable using therapies that antagonize adverse neuro-hormonal pathways (beta-blockers, angiotensin-converting-enzyme inhibitors, angiotensin receptor blockers, and mineralocorticoid antagonists) while diuretics are effective in treating congestion and HF symptoms [ 41 , 42 ]. Despite the current improvement in the management of chronic heart failure, none of the available treatments has demonstrated to improve in prognosis in acute heart failure, except a new vasodilator whose trial is still underway [ 43 , 44 ] .…”

Section: Dietary Patterns In Cardiovascular Diseasementioning

confidence: 99%

Nutrition and Cardiovascular Disease: Finding the Perfect Recipe for Cardiovascular Health

et al. 2016

Self Cite

View full text Add to dashboard Cite

The increasing burden of cardiovascular disease (CVD) despite the progress in management entails the need of more effective preventive and curative strategies. As dietary-associated risk is the most important behavioral factor influencing global health, it appears the best target in the challenge against CVD. Although for many years, since the formulation of the cholesterol hypothesis, a nutrient-based approach was attempted for CVD prevention and treatment, in recent years a dietary-based approach resulted more effective in reducing cardiovascular risk worldwide. After the publication of randomized trials on the remarkable effects of the Mediterranean diet and the Dietary Approach to Stop Hypertension (DASH) diet on CVD, new efforts were put on research about the effects of complex dietary interventions on CVD. The purpose of this paper is to review the evidence on dietary interventions in the prevention and disease modification of CVD, focusing on coronary artery disease and heart failure, the main disease responsible for the enormous toll taken by CVD worldwide.

show abstract

Serelaxin a novel treatment for acute heart failure

Cited by 8 publications

References 63 publications

KSHF Guidelines for the Management of Acute Heart Failure: Part II. Treatment of Acute Heart Failure

KSHF Guidelines for the Management of Acute Heart Failure: Part II. Treatment of Acute Heart Failure

Emerging and Traditional Treatment in Acute Heart Failure: Bad News from Last Interventional Trials

Nutrition and Cardiovascular Disease: Finding the Perfect Recipe for Cardiovascular Health

Contact Info

Product

Resources

About